vs
强生（JNJ）与摩根士丹利（MS）财务数据对比。点击上方公司名可切换其他公司
强生的季度营收约是摩根士丹利的1.4倍（$24.6B vs $17.9B），摩根士丹利净利率更高（24.6% vs 20.8%，领先3.8%）
强生是美国跨国制药、生物技术及医疗技术企业，总部位于新泽西州新不伦瑞克，在纽约证券交易所上市，普通股为道琼斯工业平均指数成分股，2025年位列财富美国500强第48位、福布斯全球企业2000强第42位。
摩根士丹利是总部位于美国纽约曼哈顿中城百老汇1585号的跨国投资银行及金融服务提供商，在全球42个国家设有办事处，员工超8万名，服务客户涵盖企业、政府、机构及个人。2023年该公司位列美国财富500强第61位，同年位居福布斯全球2000强第30位。
JNJ vs MS — 直观对比
营收规模更大
JNJ
是对方的1.4倍
$17.9B
净利率更高
MS
高出3.8%
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.6B | $17.9B |
| 净利润 | $5.1B | $4.4B |
| 毛利率 | 67.6% | — |
| 营业利润率 | 20.2% | 32.2% |
| 净利率 | 20.8% | 24.6% |
| 营收同比 | 9.1% | — |
| 净利润同比 | 49.1% | — |
| 每股收益（稀释后） | $2.08 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JNJMS
| Q4 25 | $24.6B | $17.9B | ||
| Q3 25 | $24.0B | $18.2B | ||
| Q2 25 | $23.7B | $16.8B | ||
| Q1 25 | $21.9B | $17.7B | ||
| Q4 24 | $22.5B | — | ||
| Q3 24 | $22.5B | $15.4B | ||
| Q2 24 | $22.4B | $15.0B | ||
| Q1 24 | $21.4B | $15.1B |
净利润JNJMS
| Q4 25 | $5.1B | $4.4B | ||
| Q3 25 | $5.2B | $4.6B | ||
| Q2 25 | $5.5B | $3.5B | ||
| Q1 25 | $11.0B | $4.3B | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $2.7B | $3.2B | ||
| Q2 24 | $4.7B | $3.1B | ||
| Q1 24 | $3.3B | $3.4B |
毛利率JNJMS
| Q4 25 | 67.6% | — | ||
| Q3 25 | 69.6% | — | ||
| Q2 25 | 67.9% | — | ||
| Q1 25 | 66.4% | — | ||
| Q4 24 | 68.3% | — | ||
| Q3 24 | 69.0% | — | ||
| Q2 24 | 69.4% | — | ||
| Q1 24 | 69.6% | — |
营业利润率JNJMS
| Q4 25 | 20.2% | 32.2% | ||
| Q3 25 | 31.2% | 33.1% | ||
| Q2 25 | 27.3% | 27.5% | ||
| Q1 25 | 62.3% | 31.3% | ||
| Q4 24 | 17.3% | — | ||
| Q3 24 | 14.9% | 27.4% | ||
| Q2 24 | 25.6% | 27.1% | ||
| Q1 24 | 17.4% | 29.0% |
净利率JNJMS
| Q4 25 | 20.8% | 24.6% | ||
| Q3 25 | 21.5% | 25.3% | ||
| Q2 25 | 23.3% | 21.1% | ||
| Q1 25 | 50.2% | 24.3% | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 12.0% | 20.7% | ||
| Q2 24 | 20.9% | 20.5% | ||
| Q1 24 | 15.2% | 22.5% |
每股收益（稀释后）JNJMS
| Q4 25 | $2.08 | $2.68 | ||
| Q3 25 | $2.12 | $2.80 | ||
| Q2 25 | $2.29 | $2.13 | ||
| Q1 25 | $4.54 | $2.60 | ||
| Q4 24 | $1.41 | — | ||
| Q3 24 | $1.11 | $1.88 | ||
| Q2 24 | $1.93 | $1.82 | ||
| Q1 24 | $1.34 | $2.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.1B | $111.7B |
| 总债务越低越好 | $41.4B | $341.7B |
| 股东权益账面价值 | $81.5B | $111.6B |
| 总资产 | $199.2B | $1420.3B |
| 负债/权益比越低杠杆越低 | 0.51× | 3.06× |
8季度趋势，按日历期对齐
现金及短期投资JNJMS
| Q4 25 | $20.1B | $111.7B | ||
| Q3 25 | $18.6B | $103.7B | ||
| Q2 25 | $18.9B | $109.1B | ||
| Q1 25 | $38.8B | $90.7B | ||
| Q4 24 | $24.5B | — | ||
| Q3 24 | $20.3B | $91.1B | ||
| Q2 24 | $25.5B | $90.2B | ||
| Q1 24 | $26.2B | $102.3B |
总债务JNJMS
| Q4 25 | $41.4B | $341.7B | ||
| Q3 25 | — | $324.1B | ||
| Q2 25 | — | $320.1B | ||
| Q1 25 | — | $297.0B | ||
| Q4 24 | $32.4B | — | ||
| Q3 24 | — | $291.2B | ||
| Q2 24 | — | $269.9B | ||
| Q1 24 | — | $266.1B |
股东权益JNJMS
| Q4 25 | $81.5B | $111.6B | ||
| Q3 25 | $79.3B | $110.0B | ||
| Q2 25 | $78.5B | $108.2B | ||
| Q1 25 | $78.1B | $106.8B | ||
| Q4 24 | $71.5B | — | ||
| Q3 24 | $70.2B | $103.6B | ||
| Q2 24 | $71.5B | $100.7B | ||
| Q1 24 | $70.0B | $99.2B |
总资产JNJMS
| Q4 25 | $199.2B | $1420.3B | ||
| Q3 25 | $192.8B | $1364.8B | ||
| Q2 25 | $193.4B | $1353.9B | ||
| Q1 25 | $193.7B | $1300.3B | ||
| Q4 24 | $180.1B | — | ||
| Q3 24 | $178.3B | $1258.0B | ||
| Q2 24 | $181.1B | $1212.4B | ||
| Q1 24 | $172.0B | $1228.5B |
负债/权益比JNJMS
| Q4 25 | 0.51× | 3.06× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 2.96× | ||
| Q1 25 | — | 2.78× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 2.68× | ||
| Q1 24 | — | 2.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.3B | $-2.4B |
| 自由现金流经营现金流 - 资本支出 | $5.5B | — |
| 自由现金流率自由现金流/营收 | 22.3% | — |
| 资本支出强度资本支出/营收 | 7.5% | — |
| 现金转化率经营现金流/净利润 | 1.43× | -0.55× |
| 过去12个月自由现金流最近4个季度 | $19.7B | — |
8季度趋势，按日历期对齐
经营现金流JNJMS
| Q4 25 | $7.3B | $-2.4B | ||
| Q3 25 | $9.2B | $-3.3B | ||
| Q2 25 | $3.9B | $11.8B | ||
| Q1 25 | $4.2B | $-24.0B | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $8.0B | — | ||
| Q2 24 | $5.6B | — | ||
| Q1 24 | $3.7B | $4.4B |
自由现金流JNJMS
| Q4 25 | $5.5B | — | ||
| Q3 25 | $8.0B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $7.0B | — | ||
| Q2 24 | $4.7B | — | ||
| Q1 24 | $2.9B | — |
自由现金流率JNJMS
| Q4 25 | 22.3% | — | ||
| Q3 25 | 33.4% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 20.7% | — | ||
| Q1 24 | 13.3% | — |
资本支出强度JNJMS
| Q4 25 | 7.5% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 4.4% | — | ||
| Q1 25 | 3.6% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 3.8% | — |
现金转化率JNJMS
| Q4 25 | 1.43× | -0.55× | ||
| Q3 25 | 1.78× | -0.72× | ||
| Q2 25 | 0.70× | 3.34× | ||
| Q1 25 | 0.38× | -5.56× | ||
| Q4 24 | 2.04× | — | ||
| Q3 24 | 2.97× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 1.12× | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
MS
暂无分部数据
